Patents
Literature
4 results about "Activating transcription factor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Activating transcription factor, ATF, is a group of bZIP transcription factors, which act as homodimers or heterodimers with a range of other bZIP factors. First, they have been described as members of the CREB/ATF family, whereas it turned out later that some of them might be more similar to AP-1-like factors such as c-Jun or c-Fos. In general, ATFs are known to respond to extracellular signals and this suggests an important role that they have in maintaining homeostasis. Some of these ATFs, such as ATF3, ATF4, and ATF6 are known to play a role in stress responses. Another example of ATF function would be ATFx that can suppress apoptosis.
STAT6 inhibitors and methods of use thereof
The present invention relates to novel compounds (I') which inhibit the Signal Transducer and Activator of Transcription protein 6 (STAT6). This invention also relates to pharmaceutical compositions containing them, processes for their preparation and their use in the treatment of several disorders.
Owner:ALMIRALL SA
Use of a hydrogel loaded with anti-ifn-gamma antibodies for the preparation of a medicament for the treatment of bisphosphonate-associated osteonecrosis of the jaw
The application discloses application of an anti-IFN-gamma antibody loaded hydrogel in preparation of a drug for treating bisphosphonate-related osteonecrosis of the jaw. The research result of the application shows that ZOL treatment can promote secretion of IFN-gamma by gamma delta T cells, enhance glycolysis of osteoclasts, induce histone H3K18 lactic acidification of lactic acid generated by glycolysis, activate transcription factor IKZF1 and downstream effector molecule ZBP1, finally drive necrotic apoptosis of osteoclasts and damage bone remodeling function. By locally applying GelMA@ab at a BRONJ lesion, controllable release of the anti-IFN-gamma antibody can be realized, IFN-gamma activity can be effectively blocked, necrotic apoptosis of osteoclasts and local inflammatory reaction can be significantly reduced, and a rat BRONJ-like lesion can be improved. Therefore, the application provides an effective strategy for treatment of BRONJ and provides experimental feasibility support for clinical conversion application of the composite hydrogel.
Owner:HOSPITAL OF STOMATOLOGY GUANGZHOU MEDICAL UNIVERSITY (YANGCHENG HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY)
ATF6 modulators and uses thereof
Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer. (Formula (1-2))
Owner:ALTOS LABS INC
Methods and compositions for inhibiting cell senescence
PCT designated stageWO2026064436A1Cosmetic preparationsPeptide/protein ingredientsATF3Open reading frame
The disclosure relates to methods of inhibiting cellular senescence involving expressing Activating Transcription Factor 3 (ATF3) in a cell at a level sufficient to inhibit senescence of the cell. In some embodiments, ATF3 is delivered to a cell via administration of a messenger ribonucleic acid comprising an open reading frame encoding ATF3.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE